Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311656 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants
A Phase 1 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT06311656 is a Phase 1 study that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 69 participants.
The verdict
NCT06311656, a Phase 1 study, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants. Part A consists of 2 groups and Part B, C, and D include optional groups.
Interventions
- DRUG Placebo
- DRUG LY4100511 (DC-853)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06311656
The ClinicalTrials.gov registry entry for NCT06311656 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06311656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06311656 about?
NCT06311656 is a clinical study titled "A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants". The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants. Part A consists of 2 groups and Part B, C, and D include optional groups.
What is the current status of trial NCT06311656?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2024-03-19. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT06311656?
The interventions under investigation include: Placebo (DRUG), LY4100511 (DC-853) (DRUG).
Who is sponsoring clinical trial NCT06311656?
This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.